

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 September 2021 (16.09.2021)



(10) International Publication Number
WO 2021/181366 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) *C07K 14/725* (2006.01)
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2021/052121

(22) International Filing Date:

15 March 2021 (15.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/989,071	13 March 2020 (13.03.2020)	US
62/989,093	13 March 2020 (13.03.2020)	US
62/989,120	13 March 2020 (13.03.2020)	US
62/989,187	13 March 2020 (13.03.2020)	US
62/989,230	13 March 2020 (13.03.2020)	US

(71) Applicant: **JANSSEN BIOTECH, INC** [US/US];
800/850 Ridgeview Drive Horsham, Pennsylvania, 19044
(US).

(72) Inventors: **DOONAN, Patrick, John**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **GANESAN, Rajkumar**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **DEREBE, Mehabaw, Getahun**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **VENKATARAMANI, Sathyadevi**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **SINGH, Sanjaya**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **GREWAL, Iqbal S.**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **WIEHAGEN, Karla R**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: MATERIALS AND METHODS FOR BINDING SIGLEC-3/CD33

(57) Abstract: The invention provides antigen binding domains that bind myeloid cell surface antigen CD33 protein comprising the antigen binding domains that bind CD33, polynucleotides encoding them, vectors, host cells, methods of making and using them.

WO 2021/181366 A1